{
    "id": "3427254e-c0d3-8413-e063-6394a90a766e",
    "indications": {
        "text": "carefully consider potential benefits risks diclofenac sodium extended-release tablets treatment options deciding diclofenac sodium extended-release tablets . lowest effective dose shortest duration consistent individual patient treatment goals ( ; gastrointestinal bleeding , ulceration , perforation ) . diclofenac sodium extended-release tablets indicated : relief signs symptoms osteoarthritis relief signs symptoms rheumatoid arthritis",
        "doid_entities": [
            {
                "text": "osteoarthritis (DOID:8398)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_8398"
            },
            {
                "text": "rheumatoid arthritis (DOID:7148)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_7148"
            },
            {
                "text": "arthritis (DOID:848)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_848"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "carefully consider potential benefits risks diclofenac sodium extended-release tablets treatment options deciding diclofenac sodium extended-release tablets . lowest effective dose shortest duration consistent individual patient treatment goals ( ) . observing response initial therapy diclofenac sodium extended release tablets , dose frequency adjusted suit individual patient \u2019 needs . relief osteoarthritis , recommended 100-mg daily . relief rheumatoid arthritis , recommended 100-mg daily . rare patient diclofenac sodium extended release tablets 100 mg/day unsatisfactory , dose may increased 100 mg twice day , benefits outweigh risks increased side effects . different formulations diclofenac [ voltaren \u00ae ( diclofenac sodium enteric-coated tablets ) ; diclofenac sodium extended-release tablets ; cataflam \u00ae ( diclofenac potassium immediate-release tablets ) ] necessarily bioequivalent even milligram strength .",
        "doid_entities": [
            {
                "text": "osteoarthritis (DOID:8398)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_8398"
            },
            {
                "text": "rheumatoid arthritis (DOID:7148)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_7148"
            },
            {
                "text": "arthritis (DOID:848)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_848"
            }
        ],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "diclofenac sodium extended-release tablets , usp 100 mg\u2013 pink , round , convex film coated tablets debossed ing one side 278 side . bottles 100 : ndc 68001-612-00 preserve well-closed containers . store room temperature 20\u00b0 25\u00b0c ( 68\u00b0 77\u00b0f ) ; excursions permitted 15\u00b0 30\u00b0c ( 59\u00b0 86\u00b0f ) [ usp controlled room temperature ] . protect light moisture . manufactured : ingenus pharmaceuticals nj , llc fairfield , nj 07004 bluepoint laboratories 555202 revised : 03/2024 dispense medication guide available : www.ingenus.com/medguide/bp/diclofenac-sodium-er-tablets.pdf",
    "adverseReactions": "diclofenac sodium extended-release tablets contraindicated following patients : known hypersensitivity ( e.g . , anaphylactic serious skin ) diclofenac components product ( ; anaphylactic , serious skin ) . history asthma , urticaria , allergic-type taking aspirin nsaids . severe , sometimes fatal , anaphylactic nsaids reported patients ( ; anaphylactic , ; exacerbation asthma related aspirin sensitivity ) . setting coronary artery bypass graft ( cabg ) surgery ( ; cardiovascular thrombotic events ) .",
    "ingredients": [
        {
            "name": "ANHYDROUS LACTOSE",
            "code": "3SY5LH9PMK",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17716"
        },
        {
            "name": "HYDROXYETHYL CELLULOSE, UNSPECIFIED",
            "code": "T4V6TWG28D",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11602"
        },
        {
            "name": "POVIDONE",
            "code": "FZ989GH94E",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11061"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30563"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32178"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        },
        {
            "name": "POLYETHYLENE GLYCOL, UNSPECIFIED",
            "code": "3WJQ0SDW1A",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50819"
        },
        {
            "name": "POLYSORBATE 80",
            "code": "6OZP39ZG8H",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_53426"
        },
        {
            "name": "DICLOFENAC SODIUM",
            "code": "QTG126297Q",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_4509"
        }
    ],
    "organization": "BluePoint Laboratories",
    "name": "Diclofenac sodium",
    "effectiveTime": "20250502",
    "indications_original": "Carefully consider the potential benefits and risks of diclofenac sodium extended-release tablets and other treatment options before deciding to use diclofenac sodium extended-release tablets. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see\n \n  WARNINGS;\n \n  Gastrointestinal Bleeding, Ulceration, and Perforation).\n\n \n                  Diclofenac sodium extended-release tablets are indicated:\n                  \n                     for relief of the signs and symptoms of osteoarthritis\n                     for relief of the signs and symptoms of rheumatoid arthritis",
    "contraindications_original": "Carefully consider the potential benefits and risks of diclofenac sodium extended-release tablets and other treatment options before deciding to use diclofenac sodium extended-release tablets. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see\n \n  WARNINGS).\n\n \n                  After observing the response to initial therapy with diclofenac sodium extended release tablets, the dose and frequency should be adjusted to suit an individual patient\u2019s needs.\n                  For the relief of osteoarthritis, the recommended dosage is 100-mg daily.\n                  For the relief of rheumatoid arthritis, the recommended dosage is 100-mg daily. In the rare patient where diclofenac sodium extended release tablets 100 mg/day is unsatisfactory, the dose may be increased to 100 mg twice a day, if the benefits outweigh the clinical risks of increased side effects.\n                  Different formulations of diclofenac [VOLTAREN\n \n  \u00ae(diclofenac sodium enteric-coated tablets); diclofenac sodium extended-release tablets; CATAFLAM\n \n  \u00ae(diclofenac potassium immediate-release tablets)] are not necessarily bioequivalent even if the milligram strength is the same.",
    "warningsAndPrecautions_original": "Diclofenac sodium extended-release tablets, USP\n                  \n                     100 mg\u2013 Pink, round, convex film coated tablets debossed with ING on one side and 278 on the other side.\n\n \n                  Bottles of 100: NDC 68001-612-00\n                  Preserve in well-closed containers. Store at room temperature 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F); excursions permitted between 15\u00b0 and 30\u00b0C (59\u00b0 and 86\u00b0F) [see USP Controlled Room Temperature]. Protect from light and moisture.\n                  \n                     Manufactured by:\n                  \n                  Ingenus Pharmaceuticals NJ, LLC\n                  Fairfield, NJ 07004\n                  For BluePoint Laboratories\n                  555202\n                  Revised: 03/2024\n                  Dispense with Medication Guide available at: www.ingenus.com/medguide/bp/diclofenac-sodium-er-tablets.pdf",
    "adverseReactions_original": "Diclofenac sodium extended-release tablets are contraindicated in the following patients:\n                  \n                     Known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to diclofenac or any components of the drug product (see\n  \n   WARNINGS;\n  \n   Anaphylactic Reactions,\n  \n   Serious Skin Reactions).\n \n  \n                     History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. Severe, sometimes fatal, anaphylactic reactions to NSAIDs have been reported in such patients (see\n  \n   WARNINGS;\n  \n   Anaphylactic Reactions,\n  \n   PRECAUTIONS; Exacerbation of Asthma Related to Aspirin Sensitivity).\n \n  \n                     In the setting of coronary artery bypass graft (CABG) surgery (see\u00a0\n  \n   WARNINGS;\n  \n   Cardiovascular Thrombotic Events).",
    "drug": [
        {
            "name": "Diclofenac sodium",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_4509"
        }
    ]
}